Program
baxdrostat
Also written as “Baxdrostat”, “CIN-107” and “Baxdrostat/dapagliflozin”.
Its studies are mostly in Hypertension · Renal Insufficiency, Chronic · Hyperaldosteronism · Heart Failure · Atherosclerosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 256 open or running | phase 3since Sep 6, 2023 | Aug 17, 2020 | Dec 10, 2026phase 2 · NCT07222917 |
| Hoffmann-La Roche | 10 open or running | phase 1since Nov 20, 2013 | Nov 20, 2013 | none ahead |
Also a collaborator on its studies: tigermed-consulting-co-ltd and parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Nov 20, 2013.
- Jul 3, 20234 phase 1 studies in HypertensionAstraZeneca · NCT05963009, NCT05961397, NCT05961384 and 1 more
- Sep 6, 2023Phase 3 study in HypertensionAstraZeneca · NCT06034743 · 796 enrolled · United States, Argentina, Australia and more
- Dec 5, 2023Phase 3 study in HypertensionAstraZeneca · NCT06168409 · 218 enrolled · United States, Argentina, Australia and more
- Dec 21, 2023Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06194032 · 28 enrolled · Germany
- Feb 13, 2024Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06268873 · 2,554 enrolled · United States, Argentina, Australia and more
- Mar 22, 2024Phase 2 study in Uncontrolled HypertensionAstraZeneca · NCT06336356 · 48 enrolled · United States
- Mar 27, 2024Phase 3 study in HypertensionAstraZeneca · NCT06344104 · 326 enrolled · Argentina, Australia, China and more
- Apr 5, 2024Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06357520 · 14 enrolled · United States
- Oct 23, 2024Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06657105 · 22 enrolled · United States
- Nov 5, 2024Phase 3 study in Heart FailureAstraZeneca · NCT06677060 · 11,300 planned · United States, Argentina, Australia and more
- Dec 16, 2024Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06742723 · 5,000 planned · United States, Argentina, Australia and more
- May 16, 2025Phase 3 study in HyperaldosteronismAstraZeneca · NCT07007793 · 212 enrolled · United States, Australia, Canada and more
- Oct 17, 2025Phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917 · 222 enrolled · United States, Argentina, Bulgaria and more
- May 22, 2026Phase 3 study in Uncontrolled HypertensionAstraZeneca · NCT07686120 · 286 planned · China
Ahead
- Dec 10, 2026Primary completion: phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917
- Jul 27, 2027Primary completion: phase 3 study in HyperaldosteronismAstraZeneca · NCT07007793
- Feb 9, 2028Primary completion: phase 3 study in Uncontrolled HypertensionAstraZeneca · NCT07686120
- Feb 24, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06268873
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07686120Uncontrolled Hypertension · China | 3 | Recruiting | AstraZeneca | Feb 9, 2028 | 286 |
| NCT07222917Renal Insufficiency, Chronic · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | AstraZeneca | Dec 10, 2026 | 222 |
| NCT07007793Hyperaldosteronism · United States, Australia, Canada and more | 3 | Active, not recruiting | AstraZeneca | Jul 27, 2027 | 212 |
| NCT06742723Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Dec 18, 2029 | 5,000 |
| NCT06677060Heart Failure · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Dec 17, 2029 | 11,300 |
| NCT06657105Healthy Participants · United States | 1 | Completed | AstraZeneca | Feb 3, 2025 | 22 |
| NCT06357520Healthy Participants · United States | 1 | Completed | AstraZeneca | Jun 17, 2024 | 14 |
| NCT06344104Hypertension · Argentina, Australia, China and more | 3 | Completed | AstraZeneca | Nov 24, 2025 | 326 |
| NCT06336356Uncontrolled Hypertension · United States | 2 | Completed | AstraZeneca | Dec 4, 2024 | 48 |
| NCT06268873Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Feb 24, 2028 | 2,554 |
| NCT06194032Healthy Participants · Germany | 1 | Completed | AstraZeneca | May 13, 2024 | 28 |
| NCT06168409Hypertension · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Aug 17, 2025 | 218 |
| NCT06034743Hypertension · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | May 21, 2025 | 796 |
| NCT05966324Hypertension · United States | 1 | Completed | AstraZeneca | Sep 20, 2022 | 41 |
| NCT05963009Hypertension · United States | 1 | Completed | AstraZeneca | Apr 29, 2020 | 14 |
| NCT05961397Hypertension · United States | 1 | Completed | AstraZeneca | Apr 15, 2022 | 20 |
| NCT05961384Hypertension · United States | 1 | Completed | AstraZeneca | Jan 15, 2022 | 8 |
| NCT05526690Hypertension · United States | 1 | Completed | AstraZeneca | Dec 12, 2020 | 27 |
| NCT05500820Hypertension · United States | 1 | Completed | AstraZeneca | Apr 3, 2020 | 56 |
| NCT05470725Hypertension · United States | 1 | Completed | AstraZeneca | Apr 30, 2021 | 33 |
| NCT05432167Renal Insufficiency, Chronic · United States | 2 | Completed | AstraZeneca | May 2, 2024 | 195 |
| NCT05459688Hypertension · United States | 2 | Completed | AstraZeneca | Nov 7, 2023 | 175 |
| NCT05137002Uncontrolled Hypertension · United States | 2 | Completed | AstraZeneca | Sep 13, 2022 | 249 |
| NCT04605549Hyperaldosteronism · United States | 2 | Completed | AstraZeneca | Oct 28, 2024 | 15 |
| NCT04519658Resistant Hypertension · United States | 2 | Completed | AstraZeneca | Jun 14, 2022 | 275 |
| NCT01995383Atherosclerosis · United States | 1 | Completed | Hoffmann-La Roche | Jun 2014 | 88 |
How it is read
Names in the registry
- “Baxdrostat”, 8 entries
- “CIN-107”, 7 entries
- “Baxdrostat/dapagliflozin”, 3 entries
- “baxdrostat”, 3 entries
- “RO6836191”, 3 entries
Conditions, from the studies’ own filings
- Hypertension, 15 studies
- Renal Insufficiency, Chronic, 4 studies
- Hyperaldosteronism, 2 studies
- Heart Failure, 1 study
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.